Team Blue vs Team Purple: Optimizing Frontline Treatment Strategies for the Management of EGFRm NSCLC

home / face-off / team-blue-vs-team-purple-optimizing-frontline-treatment-strategies-for-the-management-of-egfrm

Experts discuss a dynamic and multifaceted debate on frontline and subsequent treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), addressing the promise and challenges of combination therapies, central nervous system efficacy, long-term tolerability, sequencing complexities, and patient-centered decision-making in complex clinical scenarios to optimize outcomes amid evolving evidence and real-world considerations.